36 completed, 12 terminated, 9 recruiting, 7 not yet recruiting. 77 Phase 2, 8 Phase 1, 4 Phase 3.
Follow Chronic Urticaria: new trials by email Literature Review of Chronic Urticaria trials Research Report on Chronic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic | Phase 2 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2026-09-23 | 2026-09-24 |
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) THB335 Lower Dose, THB335 Higher Dose, Placebo - Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria | Phase 2 | Recruiting | Calixis Inc. | 81 | 2026-09-15 | 2026-11-02 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 140 | 2026-09-10 | 2026-08-24 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria HRS-3095 Tablet, HRS-3095 Tablet Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 190 | 2026-07-01 | 2026-05-29 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines Lesigercept, Placebo - Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Yuhan Corporation | 150 | 2026-03-26 | 2026-04-15 |
| Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria ICP-332 Tablets, ICP-332 placebo Tablets - Chronic Spontaneous Urticaria (CSU) | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 344 | 2026-02-13 | 2026-04-21 |
| Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria Ritlecitinib - Chronic Spontaneous Urticaria, CSU | Phase 2 | Withdrawn | Ahuva D Cices | 2025-12-31 | 2025-12-09 | |
| Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) CM512 injection, placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 48 | 2025-11-27 | 2026-04-09 |
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Pfizer | 200 | 2025-10-30 | 2026-10-26 |
| An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria Placebo, 0.5 mg epinephrine, 1 mg epinephrine - Urticaria Chronic | Phase 2 | Recruiting | ARS Pharmaceuticals, Inc. | 42 | 2025-07-09 | 2026-09-16 |
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) BLU-808, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 105 | 2025-05-28 | 2026-07-22 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Remibrutinib, Placebo - Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 44 | 2025-05-22 | 2026-09-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. HS-10561, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 150 | 2025-03-31 | 2025-03-07 |
| Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) EVO756, Placebo control - Chronic Spontaneous Urticaria | Phase 2 | Completed | Evommune, Inc. | 182 | 2025-03-20 | 2026-07-01 |
| Treatment Options for Chronic Urticaria Autologous serum therapy, Oral levocetirizine - Chronic Urticaria | Phase 2 | Not yet recruiting | Sheikh Zayed Medical College | 72 | 2025-02-01 | 2025-02-10 |
| Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis | Phase 2 | Terminated | InflaRx GmbH | 73 | 2025-01-02 | 2026-02-03 |
Showing 20 of 77. Sign in to see all of them.
Urticaria (17) · Cryopyrin-Associated Periodic Syndromes (11) · Pruritus (9) · Chronic Inducible Urticaria (6) · Urticaria, Solar (4) · Angioedema (2) · Bronchiolitis Obliterans Syndrome (2) · Cold Urticaria (2) · Familial dermographism (2) · Immune System Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Arthropathy, Neurogenic (1) · Behcet Syndrome (1)
Disease Attributes (77) · Hypersensitivity, Immediate (77) · Pathological Conditions, Signs and Symptoms (77) · Skin and Connective Tissue Diseases (77) · Chronic Disease (76) · Hypersensitivity (76) · Pathologic Processes (76) · Immune System Diseases (75) · Skin Diseases (75) · Skin Diseases, Vascular (75) · Urticaria (60) · Chronic Inducible Urticaria (14) · Cold Urticaria (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)
Omalizumab (10) · ligelizumab (3) · AK002 (2) · PF-06651600 (2) · canakinumab (2) · remibrutinib (2) · rilonacept (2) · AZD1981 (1) · Anti-Allergic Agents (1) · BID protein, human (1) · Cilostazol (1) · Clemastine (1) · Control Groups (1) · Diphenhydramine (1) · Dipyridamole (1)
Novartis Pharmaceuticals (9) · Genentech, Inc. (3) · Jasper Therapeutics, Inc. (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Allakos Inc. (2) · Celldex Therapeutics (2) · Centre Hospitalier Universitaire de Besancon (2) · Charite University, Berlin, Germany (2) · Evommune, Inc. (2) · Hangzhou Highlightll Pharmaceutical Co., Ltd (2) · ARS Pharmaceuticals, Inc. (1) · Aclaris Therapeutics, Inc. (1) · Ahuva D Cices (1) · Akeso (1) · Amgen (1)
United States (33) · Germany (30) · Spain (16) · Poland (15) · China (13) · Canada (10) · Japan (10) · France (8) · Taiwan (7) · Bulgaria (6) · Russia (6) · South Korea (6) · United Kingdom (6) · Greece (5) · Hungary (5)
Ahuva Cices, MD (1) · Chia Yu Chu, MD (1) · Chin Lee, MD, MPH (1) · Christopher Hull, MD (1) · David Gordon (1) · Dr Deven Parmar, MD (1)
PMID 34773261, PMID 36440464, PMID 16899778, PMID 18668591, PMID 21356079, PMID 22294344, PMID 22583335, PMID 25223501, PMID 27143789, PMID 28118536, PMID 29974963, PMID 31577874, PMID 32827729, PMID 35869554, PMID 37492920, PMID 37866460, PMID 40266575, PMID 41747871
2017 (2), 2019 (2), 2023 (2), 2009 (1), 2014 (1), 2015 (1), 2018 (1), 2025 (1), ZIAAR041138-08 (1)